Galcanezumab

Limits on what this shows

• Key negative/null findings: None reported. This is a positive-outcome case series with no comparator arm, so there is no null or negative finding on record, and the authors themselves call for larger studies before drawing broader conclusions.
• At-risk subgroups: The entry's own population is itself the at-risk subgroup, patients with pre-existing primary mitochondrial disease. The case report's finding is that this subgroup tolerated galcanezumab well, not that the drug harmed it, but n=2 cannot establish subgroup-level safety.

Regulatory status

Not addressed in Emgality labeling. Mitochondrial disease is not a named population, warning, or contraindication on the label (confirmed by direct re-read of the full label this pass).

Population evidence

Silvestro M, Orologio I, Trojsi F, Tessitore A, Tedeschi G, Russo A. Effectiveness and safety of CGRP monoclonal antibodies in migraine related to mitochondrial diseases in patients with NARP and PEO syndromes. Clin Neurol Neurosurg. 2023 Mar. DOI 10.1016/j.clineuro.2023.107611. Case report, n=2 (both female), one with NARP syndrome and one with PEO syndrome, both with chronic, treatment-resistant migraine, both treated with galcanezumab specifically. Both patients showed what the authors call a "brilliant response" in attack frequency, intensity, and duration; one case improved from roughly 20 monthly attacks at severity 9/10 at baseline.

Mechanism

Proposed, not measured: the authors hypothesize that CGRP monoclonal antibodies "may modulate dysfunctional glycolytic metabolism in trigeminal ganglion," a named but unconfirmed mechanism. No electron-transport, membrane-integrity, or biogenesis marker was measured in either patient; the full discussion section elaborating this hypothesis was not accessible beyond the abstract/highlights during this pass.

Counter-evidence held on record

n=2, single center, no comparator arm, and no mitochondrial biomarker (lactate, electron-transport-chain enzyme activity, muscle biopsy) was measured in either patient. This does not establish, and must never be read as establishing, that galcanezumab affects mitochondrial structure or function in either direction for the general treated population. This is reassuring tolerability evidence in a specific vulnerable subgroup, not a mitochondrial-burden deficiency claim and not a basis for any supplement recommendation.

Limits on what this shows

• Key negative/null findings: Ferric-reducing antioxidant power (FRAP) and thiol groups (-SH), the two biomarkers measuring antioxidant capacity rather than oxidative damage, showed no significant change at any follow-up point.
• At-risk subgroups: None identified. Cohort was treatment-resistant chronic migraine; not generalizable to first-line or treatment-naive use.

Regulatory status

Not addressed in FDA or EMA labeling. Oxidative-stress biomarkers are not part of any required or recommended monitoring for this drug.

Population evidence

De Luca et al., 2021, Journal of Clinical Medicine 10(19):4586 (DOI 10.3390/jcm10194586). Prospective observational study, treatment-resistant migraine (failed 4+ prior prophylactic classes), University of Pisa Headache Centre, July 2020 to June 2021. n=42 total (17 galcanezumab 240 mg load/120 mg monthly, 23 erenumab 70 mg, 2 fremanezumab 225 mg), baseline (T0) through 6-month follow-up (T3). AOPP fell from median 291.4 nmol/L (IQR 154.25) at T0 to 236.2 nmol/L (IQR 111.2) at T3, p=0.004.

Mechanism

Named but not confirmed to be CGRP-blockade-specific: reduced migraine-attack frequency and the associated neuroinflammatory/oxidative burst is the proposed driver, rather than a direct antioxidant action of the antibody itself.

Counter-evidence held on record

Results are pooled across three different CGRP antibodies (galcanezumab, erenumab, fremanezumab) with no drug-stratified subgroup analysis reported, so the galcanezumab-specific contribution to the AOPP change cannot be isolated. There is no placebo or untreated comparator arm, so fewer migraine attacks overall, rather than CGRP blockade specifically, is a live competing explanation (confounding by indication, Hard Rule 6). Single center, single study, not independently replicated. This is a reassuring, not a deficiency, signal. It never implies galcanezumab should be used to treat oxidative stress, and it carries no supplementation recommendation in either direction.

Limits on what this shows

• Key negative/null findings: No galcanezumab trial safety summary reviewed for this dossier (REGAIN, EVOLVE-1/2, CONQUER, and their open-label extensions) reports anemia or iron deficiency as a treatment-emergent signal.
• At-risk subgroups: Pre-existing iron deficiency is common in migraine patients broadly, particularly menstruating women, independent of which prophylactic therapy, if any, they receive.

Regulatory status

Not addressed anywhere in the Emgality label. Iron is not a named interaction or monitoring parameter.

Population evidence

Al-Qassab et al., 2024, Cureus (DOI 10.7759/cureus.69652), narrative literature review of iron deficiency anemia and migraine as a disease association. No CGRP monoclonal antibody, galcanezumab, or any migraine-prophylaxis drug is in the reviewed cohort; this is disease-epidemiology literature, not drug-safety literature, and does not pass the Step 4 cohort test above Tier C/D for galcanezumab.

Mechanism

None specific to galcanezumab. The proposed disease-level mechanism concerns iron's role in neurovascular and neurotransmitter function, unrelated to CGRP-antibody pharmacology.

Counter-evidence held on record

Confounding by indication is the default explanation here (Hard Rule 6): any iron deficiency observed in a galcanezumab-treated migraine population is, on current evidence, attributable to the underlying migraine population's baseline iron status, not to the drug. This is a population-context flag, not a galcanezumab-specific deficiency claim. Do not attribute a patient's iron deficiency to galcanezumab therapy; evaluate it the same way it would be evaluated in any migraine patient, drug-treated or not.

Limits on what this shows

• Why no grade: Channels tried this pass: WebFetch to pubmed.ncbi.nlm.nih.gov, api.crossref.org, api.openalex.org, api.semanticscholar.org, www.ebi.ac.uk (Europe PMC REST API), eutils.ncbi.nlm.nih.gov, dailymed.nlm.nih.gov, openalex.org, doi.org, onlinelibrary.wiley.com, and frontiersin.org all failed with the same outcome, confirmed by a direct curl test against the agent proxy run this pass (see proxy status endpoint): HTTP 403 CONNECT rejected at the organization's network policy level, not a rate limit and not a transient failure, across every one of these hosts without exception. Search/listing pages on hosts that did load were separately blocked by robots.txt (pmc.ncbi.nlm.nih.gov search listings, html.duckduckgo.com, www.bing.com, www.google.com, www.mdpi.com/search) or redirected to an Elsevier login wall (www.sciencedirect.com/search), so no copper-specific query could actually be run against a working search index this pass, only against individually named article URLs already known from this batch's prior work. Two such direct fetches succeeded and confirmed no copper mention: the fremanezumab pooled phase 3 safety analysis (PMC9218411) and a direct re-read of the full Emgality label (no hemoglobin, hematocrit, anemia, or copper mentioned anywhere). WebSearch was exhausted (0 of 200 calls remaining session-wide) before this category could be queried that way. No circulating consumer claim linking galcanezumab, or any CGRP monoclonal antibody, to copper was found in the drug-nutrient-depletion compendia already checked (see Sources). The three sibling CGRP monoclonal antibody dossiers in this B009 batch (erenumab, fremanezumab, eptinezumab) were cross-checked this pass per the cohort-test instruction and all three independently reached the same ungraded result for Copper, with no sibling surfacing a usable drug- or class-level lead.

Disposition

Most plausibly a genuine literature gap, since a subcutaneously injected, non-chelating, non-renally-active IgG4 antibody with no oral-absorption step has no a priori copper-handling mechanism, but this cannot be certified as a settled gap while every dedicated literature-search index (PubMed, Crossref, OpenAlex, Semantic Scholar, Europe PMC) remains blocked at the organization policy level rather than merely rate-limited. This is a disclosed tooling limitation, not a finding of safety; a future revision should re-run a direct copper-specific query against these indexes the moment any one of them becomes reachable, before treating this gap as settled. Copper is kept as its own independent entry per Hard Rule 7 and is never merged with Iron above.

Limits on what this shows

• Key negative/null findings: A transgenic-mouse charcoal-meal transit study (Johnson et al., 2022, Headache, DOI 10.1111/head.14336) found galcanezumab itself produced no statistically significant change in large-intestinal transit, while small-molecule CGRP-receptor antagonists (telcagepant, atogepant) significantly slowed transit, in tension with the positive human constipation-score finding above.
• At-risk subgroups: None specifically identified; patients with pre-existing GI motility disorders were excluded from the RCT, so risk in that population is unstudied.

Regulatory status

Constipation, including severe cases requiring hospitalization or surgery, is listed in Emgality's postmarketing adverse reactions (USPI Section 6.3). The label does not characterize this as a microbiome-level effect.

Population evidence

Kudrow et al., 2022, Headache (DOI 10.1111/head.14390), NCT04294147. Phase 4 randomized trial, n=65 episodic-migraine patients without significant baseline GI symptoms, randomized to galcanezumab or erenumab. Galcanezumab arm: gastrointestinal symptom rating scale, constipation domain, least-squares mean change +0.4 from baseline, p=.002 (worsening). No severe treatment-emergent adverse events in either arm.

Mechanism

Plausible, general physiology only, not galcanezumab-specific: CGRP has an established role in gastrointestinal motor and secretory function, and slower large-intestinal transit is a non-drug-specific mechanism by which gut bacterial composition can shift (longer dwell time, altered short-chain-fatty-acid and bile-acid handling) in the broader GI-physiology literature. That general transit-microbiome link is Tier C/D background used only to explain plausibility, not as direct evidence of a galcanezumab-associated microbiome change.

Counter-evidence held on record

Animal-model null result above. The RCT used an active comparator (erenumab), not a placebo, so neither drug is compared against no treatment. No microbiome sequencing or stool-composition data exists for any CGRP monoclonal antibody at the drug or class level despite a genuine multi-channel search (see Sources). This entry grades a plausible secondary mechanism, not the constipation symptom itself, which is the drug's own labeled adverse reaction and an outcome, not a nutrient deficiency (Hard Rule 2). No probiotic, fiber, or supplement recommendation is made on this basis.

Limits on what this shows

• Key negative/null findings: Confirmed by direct re-read of the full label this pass: hemoglobin, hematocrit, anemia, and copper are not mentioned anywhere in the Emgality label. This is a vessel-tone effect, not a change in blood oxygen-carrying capacity.
• At-risk subgroups: Patients with pre-existing hypertension or Raynaud's phenomenon, per the label's own monitoring language.

Regulatory status

Emgality USPI Warnings and Precautions 5.3 (Hypertension) and 5.4 (Raynaud's Phenomenon); Section 6.3 (postmarketing adverse reactions) lists both under Vascular Disorders. Re-read directly in full this pass.

Population evidence

Label text, verified directly this pass: hypertension "may occur at any time during treatment but was most frequently reported within 7 days of therapy initiation"; the label directs monitoring for new-onset or worsening hypertension and discontinuation if an alternative cause is not established or blood pressure stays uncontrolled. Raynaud's phenomenon: median symptom onset 71 days post-dose across monoclonal-antibody CGRP antagonists; the label directs discontinuation if symptoms develop.

Mechanism

Named and drug-specific: CGRP is an endogenous vasodilator; antibody neutralization of circulating CGRP removes this vasodilatory tone, which can unmask vasoconstriction or vasospasm in susceptible patients. This is the same CGRP-blocking action that produces the drug's intended migraine-preventive effect, not a separate nutrient-handling pathway.

Counter-evidence held on record

No hemoglobin, hematocrit, or tissue-hypoxia signal is reported anywhere in the label or in any source reviewed for this dossier; the vascular signal is hemodynamic (vessel tone), not an oxygen-carrying-capacity signal. Per Hard Rule 2, a drug's own intended or labeled pharmacologic effect on blood vessels is not filed as a nutrient deficiency. No iron, copper, or B12 supplement is implicated by this entry. Monitor blood pressure and vasospasm symptoms clinically per the label, not through diet or supplementation.

Limits on what this shows

• Key negative/null findings: No galcanezumab trial safety summary reviewed for this dossier (REGAIN, EVOLVE-1/2, CONQUER, and their open-label extensions) reports a metabolic or energy-related laboratory signal in either direction.
• At-risk subgroups: None identified.
• Counter-evidence on record: No human clinical confirmation exists in either direction; the rodent mechanism may not translate to this antibody or to humans.

Regulatory status

Not addressed in the Emgality label; not a recognized adverse-effect category.

Population evidence

None in humans and none in galcanezumab-treated patients specifically. The only supporting data are rodent and mechanistic.

Mechanism

Ramirez-Exposito MJ, Cueto-Urena C, Martinez-Martos JM. Calcitonin Gene-Related Peptide (CGRP): Biology, Signaling, Pathophysiological Roles, and Therapeutic Applications. Int J Mol Sci. 2026;27(11):4973. DOI 10.3390/ijms27114973. Verified directly this pass: "endogenous CGRP contributes to high-fat-diet-induced weight gain by inhibiting sympathetic activity and reducing energy expenditure; its blockade improves insulin sensitivity and reduces adiposity in murine obesity models." This is class-level and mechanistic: it concerns CGRP blockade broadly (genetic or pharmacologic, in mice), not galcanezumab by name, and the cohort is mice, not a galcanezumab clinical population, so it is Tier C/B for this specific drug under the cohort test. Galcanezumab neutralizes the CGRP ligand itself, the same pharmacological direction as fremanezumab (as opposed to erenumab, which blocks the receptor), so the mechanism described applies with equal plausibility.

Counter-evidence held on record

Reverse-direction and purely theoretical; this is explicitly not a basis for any ATP-support or energy supplement recommendation.